A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III)
出版年份 2017 全文链接
标题
A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III)
作者
关键词
-
出版物
Annals of Clinical and Translational Neurology
Volume 4, Issue 6, Pages 360-368
出版商
Wiley
发表日期
2017-05-09
DOI
10.1002/acn3.412
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease
- (2016) Cindy J. Nowinski et al. MOVEMENT DISORDERS
- Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries
- (2014) Marlene C. Hechtner et al. PARKINSONISM & RELATED DISORDERS
- A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
- (2014) et al. JAMA Neurology
- Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)
- (2013) MOVEMENT DISORDERS
- Use of Calcium Channel Blockers and Parkinson’s Disease
- (2012) Björn Pasternak et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Cognitive Impairment in Parkinson Disease
- (2012) Iracema Leroi et al. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
- Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1
- (2012) Jordan J. Elm et al. MOVEMENT DISORDERS
- Psychosis, apathy, depression and anxiety in Parkinson's disease
- (2012) David A. Gallagher et al. NEUROBIOLOGY OF DISEASE
- Dihydropyridine calcium channel blockers and the progression of parkinsonism
- (2011) Connie Marras et al. ANNALS OF NEUROLOGY
- Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine
- (2011) Thimmappa S. Anekonda et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
- (2011) Olivier Rascol et al. LANCET NEUROLOGY
- Interpreting the results of Parkinson's disease clinical trials: Time for a change
- (2011) Nick H. G. Holford et al. MOVEMENT DISORDERS
- The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease
- (2011) Pablo Martinez-Martin et al. MOVEMENT DISORDERS
- The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
- (2011) E. Ilijic et al. NEUROBIOLOGY OF DISEASE
- Calcium channel blocker use and risk of Parkinson's disease
- (2010) Kelly Claire Simon et al. MOVEMENT DISORDERS
- Systematic review of levodopa dose equivalency reporting in Parkinson's disease
- (2010) Claire L. Tomlinson et al. MOVEMENT DISORDERS
- Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease
- (2009) Sotirios A. Parashos ARCHIVES OF NEUROLOGY
- A longitudinal program for biomarker development in Parkinson's disease: A feasibility study
- (2009) Bernard Ravina et al. MOVEMENT DISORDERS
- Neuroprotection trials in Parkinson's disease: Systematic review
- (2009) Robert G. Hart et al. MOVEMENT DISORDERS
- What should be defined as good outcome in stroke trials; a modified Rankin score of 0–1 or 0–2?
- (2008) N. Weisscher et al. JOURNAL OF NEUROLOGY
- Expression and 1,4-Dihydropyridine-Binding Properties of Brain L-Type Calcium Channel Isoforms
- (2008) M. J. Sinnegger-Brauns et al. MOLECULAR PHARMACOLOGY
- Use of antihypertensives and the risk of Parkinson disease
- (2008) C. Becker et al. NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started